Statins and cardiovascular protection: Main purpose: Decrease of the LDL-cholesterol;Les statines pour la prévention cardio-vasculaire: L'abaissement du LDL-cholestérol, objectif principal

Presse Medicale

Volumn 31, Issue 30, 2002, Pages 1428-1433

  Fruchart, Jean Charles ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG ABSORPTION; HEART PROTECTION; HUMAN; MORTALITY; REVIEW; RISK FACTOR; ARTICLE; BLOOD; CAUSE OF DEATH; CORONARY ARTERY ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; SURVIVAL RATE;

ANTICHOLESTEREMIC AGENTS; CAUSE OF DEATH; CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; SURVIVAL RATE;

EID: 0037151794     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-76.
2. Castelli WP, Anderson K, Wilson PW et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992; 2: 23-8.
3. LaRosa JC, Hunninghake D, Bush D et al The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation 1990; 81: 1721-33.
4. Verschuren WMM, Jacobs DR, Bloemberg BPM et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA 1995; 274: 131-6.
5. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 (Suppl A): A2-A11.
6. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-S03.
7. Chen Z, Peto R, Collins R, McMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303: 276-82.
8. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greeland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284: 311-18.
9. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998; 82:3Q-12Q.
10. Gotto AM. Lipid-lowering therapy for the primary prevention of coronary heart disease. J Am Coll Cardiol 1999; 33: 2078-82.
11. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995; 91: 2274-82.
12. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
13. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
14. The Long-term Intervention with Pravastatin in Ischaemic Disease (UPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
15. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
16. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
17. Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med 1998; 158:1977-89.
18. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD, Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 1998; 97: 946-52.
19. Crouse JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998; 138: 11-24.
20. Byington RP, Davis BR, Plehn JF et al. Reduction of stroke events with pravastatin. The Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103: 387-92.
21. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999; 10: 543-59.
22. Recommandations de l'AFSSAPS. Prise en charge thérapeutique des patients dyslipidémiques. Septembre 2000. www.agmed.sante.gouv.fr
23. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
24. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001; 28S: 1711-8.
25. Thompson GR, Barter PJ. Clinical lipidology at the end of the millennium. Curr Opin Lipidol 1999; 10: S21-6.
26. Holme I. Lipid lowering in the patient at risk - the next decade of discovery. Br J Cardiol 2000; 7: 223-30.
27. Davidson MH. Statin trials in progress: unanswered questions, Curr Atheroscl Rep 2001; 3: 9-13.
28. Pedersen TR. Aggressive lipid-lowering therapy: a clinical imperative. Eur Heart J 1998; 19(Suppl M): M1-M21.
29. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997; 336: 153-62.
30. Smilde TJ, Van Wissen S, Wollersheim H, Trip MD, Kastelein JJP, Stalenhoef AFH. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 3S7: S77-81.
31. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
32. Muls E, De Backer G, De Bacquer D, Brohet M, Heller F. LIPIWATCH, a Belgian/luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin Drug Invest 2000; 19: 219-29.
33. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-72.
34. Pedersen TR. Pro and Con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. Am J Cardiol 2001; 87(Suppl): 8B-12B.
35. Grundy SM. Primary prevention of coronary heart disease. Circulation 1999; 100: 988-98.
36. Brown WV. Novel approaches to lipid lowering: what is on the horizon? Am J Cardiol 2001; 87(Suppl): 23B-27B.
37. McTaggart F, Buckett L, Davidson R et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor. Am J Cardiol 2001; 87(Suppl): 28B-32B.
38. Olsson AG. Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. Am J Cardiol 2001; 87 (Suppl): 33B-36B.
39. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. ZD 4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines. J Am Coll Cardiol 2001; 37(suppl): 291A.
40. Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-75.
41. Stein E, Strutt KL, Miller E, Southworth H. ZD 4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001; 37(Suppl): 292A.